Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commission Would Back Limited Expansion Of Products Covered By MDR Grace Period

Executive Summary

There has been much speculation recently over whether the European Commission is supporting a proposal to expand the range of products covered by the four-year grace period under the Medical Device Regulation. Many have urged caution at the news, but now the commission has spoken out.

You may also be interested in...



UK Medtech Ponders Post-Brexit Regulatory Future At APPG

The consensus among the UK MHRA, the national medtech industry and notified bodies remains that convergence of regulatory systems is the preferred route for the UK once it has left the EU. Meanwhile, the regulator is planning for all eventualities, as a recent parliamentary forum on the post-Brexit regulatory landscape heard.

To Ensure Continued Availability Of Self-Care Devices In Europe, EU Commission Must 'Stop The Clock' On MDR

As the implementation deadline for the European Union's Medical Devices Regulation creeps ever closer, substance-based medical devices such as nasal sprays and throat lozenges are in danger of slipping through the net of re-certification. TÜV SÜD, one of only four notified bodies to be approved for re-certification under the new rules, says the EU should "stop the clock" on implementation to ensure these products continue to be available in Europe after the deadline. 

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel